Roundtable Discussion; The Future of Mineral Sands. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksAstrazeneca Share News (AZN)

Share Price Information for Astrazeneca (AZN)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 12,050.00
Bid: 12,038.00
Ask: 12,040.00
Change: -106.00 (-0.87%)
Spread: 2.00 (0.017%)
Open: 12,092.00
High: 12,178.00
Low: 12,010.00
Prev. Close: 12,156.00
AZN Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

UPDATE 4-Germany sees rapid EU approval of AstraZeneca's COVID-19 vaccine

Wed, 30th Dec 2020 11:06

(Adds report on lockdown extension)

By Kirsti Knolle and Douglas Busvine

BERLIN, Dec 30 (Reuters) - Germany expects the European
Union to give rapid approval to the coronavirus vaccine
developed by Oxford University and AstraZeneca that was
cleared for use in Britain on Wednesday, its top vaccines
official said.

Berlin's support for AstraZeneca comes as EU member
countries seek to fill supply chains for vaccination drives that
began last weekend using a shot from Pfizer and BioNTech
- the only one to win EU approval so far.

Germany has made relatively quick headway, saying 78,000
shots have been administered, but there have been reports of
setbacks with some vaccination centres shutting down temporarily
because of supply shortages.

Responding to complaints in the capital Berlin and in the
federal states of Brandenburg and Bavaria of delays in
delivering the Pfizer vaccine, the Health Ministry said further
shipments were due on Jan. 8 and Jan. 18.

Fatalities linked to COVID-19 in Germany hit a record daily
high of 1,129 on Wednesday, bringing total deaths to 32,107, as
local authorities caught up with a Christmas reporting backlog.
Total confirmed cases reached 1.69 million.

The mass-selling Bild newspaper reported that Chancellor
Angela Merkel's chief of staff had agreed during a video
conference with regional leaders to extend a lockdown until Jan.
24 or 31.

Merkel will finalise the date and details of the measures
during talks with regional leaders in the new year.

Klaus Cichutek, head of the Paul Ehrlich Institute, said
that, thanks to the rolling EU review of the AstraZeneca
vaccine, it would be possible to take a quick decision once a
formal application was submitted.

No such application had been received by the European
Medicines Agency (EMA) by Wednesday morning, Cichutek told
reporters, but a debate in its councils would follow as soon as
it arrived.

"Once the application is submitted a decision can be taken
quickly," Cichutek told a news conference.

"THOROUGH AND QUICK"

German Health Minister Jens Spahn urged "a thorough and
quick examination" of the AstraZeneca vaccine by EMA, in
addition to the expected clearance of a shot from Moderna
in early January.

"Vaccination is the key to getting out of this pandemic,"
Spahn told reporters.

"Preventing death and suffering is key. It is the key to
getting our normal lives back."

Spahn confirmed that Germany still expected to take delivery
of 1.3 million doses of the Pfizer shot by the end of the year.
Then, after the two consignments in January, weekly shipments of
670,000 doses would follow each Monday, his ministry said.

Even with increased supply going into early 2021, it will
take months to inoculate the wider population.

"I can only appeal for patience," he said. "Please don't
forget that we have a vaccine ... that is reason enough for joy
and optimism."

Amid heightened contagion, continued strong reductions of
social contacts would continue to be necessary, officials said.

"It will take months until enough people are vaccinated to
reduce the circulation of the virus in the population," said
Lothar Wieler, head of the Robert Koch Institute responsible for
coordinating Germany's pandemic response.

(Writing by Douglas Busvine; Editing by John Stonestreet and
Alison Williams)

More News
3 May 2024 12:17

CORRECT: Angle shares up on assay development deal with AstraZeneca

(Correcting company name in headline)

Read more
3 May 2024 11:50

Angle shares up on assay development deal with AstraZenaca

(Alliance News) - Shares in Angle PLC jumped on Friday, after the company said it has been chosen to develop a prostate cancer assay using its Parsortix technology, opening the door for future clinical study-supporting contracts.

Read more
3 May 2024 07:50

LONDON BRIEFING: InterContinental Hotels makes first-quarter progress

(Alliance News) - London's FTSE 100 is called to open higher on Friday, on the expectation of a softer US jobs report, which could take some sting out of hawkish Federal Reserve interest rate expectations.

Read more
2 May 2024 10:04

AstraZeneca notes positive trial results for Calquence treatment

(Alliance News) - AstraZeneca PLC on Thursday said it observed positive high-level results in the Echo phase 3 trial of its Calquence treatment for previously untreated adult patients with mantle cell lymphoma.

Read more
2 May 2024 07:45

AstraZeneca reports positive results from blood cancer drug trial

(Sharecast News) - AstraZeneca has reported positive results from the use of its Calquence drug in a clinical trial to treat a rare type of blood cancer.

Read more
29 Apr 2024 22:52

J&J, Bristol Myers lose challenges to US drug price negotiation program

April 29 (Reuters) - A U.S. judge on Monday rejected a challenge by Bristol Myers Squibb and Johnson & Johnson to a law requiring them to negotiate the prices of their blockbuster blood clot prevention drugs with the U.S government's Medicare health insurance program or pay heavy penalties.

Read more
29 Apr 2024 10:02

LONDON BROKER RATINGS: Deutsche Bank likes Frasers; Barclays cuts JD

(Alliance News) - The following London-listed shares received analyst recommendations Monday morning and Friday:

Read more
29 Apr 2024 09:13

AstraZeneca makes progress with Truqap and Enhertu cancer treatments

(Alliance News) - AstraZeneca PLC on Monday said its Truqap drug has been recommended for approval in the EU to treat a form of breast cancer, while also noting trial results for its Enhertu offering.

Read more
29 Apr 2024 07:50

LONDON BRIEFING: Hipgnosis Songs Fund backs new Blackstone bid

(Alliance News) - London's FTSE 100 is called to open higher on Monday, with heady gains for US tech stocks on Friday brightening the mood in Europe and Asia at the start of the new week.

Read more
29 Apr 2024 07:24

AstraZeneca makes progress with two breast cancer treatments

(Sharecast News) - AstraZeneca issued favourable updates on two of its breast cancer treatments on Monday - 'Truqap', or capivasertib, and 'Enhertu', or trastuzumab deruxtecan - following encouraging results from respective phase three trials.

Read more
26 Apr 2024 09:33

LONDON BROKER RATINGS: Peel Hunt cuts ConvaTec to 'reduce'

(Alliance News) - The following London-listed shares received analyst recommendations Friday morning:

Read more
25 Apr 2024 16:57

LONDON MARKET CLOSE: FTSE 100 shakes off red-hot US inflation gauge

(Alliance News) - London's FTSE 100 outperformed on Thursday, enjoying a solid rise on largely well-received corporate earnings and a share price jump for miner Anglo American after it received a takeover bid from peer BHP.

Read more
25 Apr 2024 15:14

London close: Stocks finish mixed as US GDP growth slows

(Sharecast News) - London's stock markets finished with a mixed performance on Thursday, as investors digested a slower-than-expected GDP growth reading from the United States, while a slew of well-received earnings underpinned the top-flight index.

Read more
25 Apr 2024 11:50

LONDON MARKET MIDDAY: FTSE 100 hits high on offer for Anglo American

(Alliance News) - The FTSE 100 was outperforming European markets at midday on Thursday, with the index boosted to a record high thanks to takeover talks.

Read more
25 Apr 2024 10:33

AstraZeneca leaps after smashing first-quarter forecasts

Q1 revenue up 19% to $12.68 bln

*

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.